CA2717915A1 - Chemoprotective methods and compositions - Google Patents

Chemoprotective methods and compositions Download PDF

Info

Publication number
CA2717915A1
CA2717915A1 CA2717915A CA2717915A CA2717915A1 CA 2717915 A1 CA2717915 A1 CA 2717915A1 CA 2717915 A CA2717915 A CA 2717915A CA 2717915 A CA2717915 A CA 2717915A CA 2717915 A1 CA2717915 A1 CA 2717915A1
Authority
CA
Canada
Prior art keywords
composition
once
salt
chemotherapeutic agent
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2717915A
Other languages
English (en)
French (fr)
Inventor
Frederick H. Hausheer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioNumerik Pharmaceuticals Inc
Original Assignee
BioNumerik Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNumerik Pharmaceuticals Inc filed Critical BioNumerik Pharmaceuticals Inc
Publication of CA2717915A1 publication Critical patent/CA2717915A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2717915A 2008-03-14 2008-03-14 Chemoprotective methods and compositions Abandoned CA2717915A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/003406 WO2009113984A1 (en) 2008-03-14 2008-03-14 Chemoprotective methods and compositions

Publications (1)

Publication Number Publication Date
CA2717915A1 true CA2717915A1 (en) 2009-09-17

Family

ID=41065493

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2717915A Abandoned CA2717915A1 (en) 2008-03-14 2008-03-14 Chemoprotective methods and compositions

Country Status (6)

Country Link
EP (1) EP2252246B1 (enExample)
JP (1) JP5667885B2 (enExample)
AU (1) AU2008352598B2 (enExample)
CA (1) CA2717915A1 (enExample)
ES (1) ES2476602T3 (enExample)
WO (1) WO2009113984A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2984379C (en) * 2015-04-28 2024-06-11 Newsouth Innovations Pty Limited Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity
KR20200028950A (ko) * 2017-06-14 2020-03-17 에이디씨 테라퓨틱스 에스에이 항-cd25 adc의 투여를 위한 투약량 체제
KR20210062029A (ko) 2018-10-19 2021-05-28 에스케이바이오팜 주식회사 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도
SG11202109705YA (en) * 2019-03-08 2021-10-28 Lantern Pharma Inc Method for treating female non-smokers with non-small cell lung cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7021A (en) * 1850-01-15 Substitute for the clevis
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US6037336A (en) 1996-09-23 2000-03-14 Bionumerik Pharmaceuticals, Inc. Reducing toxic effects of carboplatin using dithioethers
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
WO2002056755A2 (en) * 2001-01-19 2002-07-25 Bionumerik Pharmaceuticals, Inc. Method for treating cancer
US7176192B2 (en) * 2001-10-26 2007-02-13 Bionumerik Pharmaceuticals, Inc. Method for treating patients for radiation exposure
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US20050158356A1 (en) * 2003-11-20 2005-07-21 Angiotech International Ag Implantable sensors and implantable pumps and anti-scarring agents
US20050256055A1 (en) * 2004-05-12 2005-11-17 Hausheer Frederick H Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
WO2007070599A2 (en) * 2005-12-13 2007-06-21 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions

Also Published As

Publication number Publication date
AU2008352598A1 (en) 2009-09-17
EP2252246B1 (en) 2014-06-18
JP5667885B2 (ja) 2015-02-12
EP2252246A4 (en) 2011-10-26
AU2008352598B2 (en) 2012-06-07
JP2011514356A (ja) 2011-05-06
WO2009113984A1 (en) 2009-09-17
ES2476602T3 (es) 2014-07-15
EP2252246A1 (en) 2010-11-24

Similar Documents

Publication Publication Date Title
US8143236B2 (en) Chemoprotective methods
AU2007227466B2 (en) Anti-cancer activity augmentation compounds and formulations and methods of use thereof
AU2021202433A1 (en) Neuroactive steroids, compositions, and uses thereof
RU2662298C2 (ru) Лечение рака комбинацией плинабулина и таксана
CA2648945C (en) Chemoprotective methods and compositions
JP2011140521A (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
KR20200118823A (ko) 펜타아자 마크로시클릭 고리 복합체 및 백금-기재 항암제를 사용한 조합 암 요법
AU2008352598B2 (en) Chemoprotective methods and compositions
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
TW200803842A (en) Antineoplastic combinations of temsirolimus and sunitinib malate
Merheb et al. Drug-induced peripheral neuropathy: diagnosis and management
CN109641009A (zh) 抗肿瘤剂、抗肿瘤效果增强剂及抗肿瘤用试剂盒
JP2012527424A (ja) イネカルシトールの新しい治療的使用
US10786505B2 (en) Administration of NEDD8-activating enzyme inhibitor and chemotherapeutic agents
JP2008169220A (ja) 癌を処置または予防するためのβ−ラパコンの使用
TW201249435A (en) Antitumoral combination comprising cabazitaxel and cisplatin
EP2262493A1 (en) Methods of treatment employing prolonged continuous infusion of belinostat
KR20180006417A (ko) 카바지탁셀 및 암 치료에 대한 그의 용도
JP2019131508A (ja) ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
Davis et al. Chemotherapy and hormonal therapy
UA16885U (en) Method for preventing hypoxic consequences of blood loss in labor

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20170118